We are on the same page.
Why would Mesoblast change tact?
It wouldn't be easy to get another group to fund for the adult GVHD trial - why get it so far and then put it on hold?
Mesoblast was on its knees.
Having being forced to do a CR at such a low level of 30c, highly dilutive.
You don't do that unless you are desperate for cash.
To then put $10m of CR money into debt reduction and pausing the adult GVHD trial - Mesoblast must have received clear and positive feedback to resubmit the Ryoncil BLA.
As a change of approach must be internally debated and rectified.
GG and the board are backing this approach, hence the on market buy-in.
Anyway, things are looking good. I'm more than ready to enjoy the fun part of this ride!
GL MSB'ers - onwards and upwards
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA, page-733
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.39 |
Change
0.000(0.00%) |
Mkt cap ! $1.581B | |||
| Open | High | Low | Value | Volume |
| $1.40 | $1.42 | $1.38 | $3.791M | 2.722M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 23596 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.39 | 23299 | 7 |
View Market Depth
| Last trade - 15.37pm 10/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |